Indeed, TP53 alterations in CLL are responsible for primary resistance to fludarabine and survival of such patients is clearly improved by new-targeted therapies, such as ibrutinib [5, 6]. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.